Incident bisphosphonate use and risk of knee replacement surgery among women with incident knee osteoarthritis  by Neogi, T. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A6773
DYSREGULATED CIRCADIAN RHYTHM PATHWAY IN HUMAN
OSTEOARTHRITIS: NR1D1 AND BMAL1 SUPPRESSION ALTERS TGF-В
AND IL-1В SIGNALING IN CHONDROCYTES
R. Akagi y, K.M. Fisch y, O. Alvarez-Garcia y, T. Teramura y,
Y. Muramatsu y, M. Saito z, T. Sasho x, A.I. Su y, M.K. Lotz y. y The Scripps
Res. Inst., La Jolla, CA, USA; z Toho Univ. Sakura Med. Ctr., Sakura, Japan;
xChiba Univ., Chiba, Japan
Purpose: Circadian rhythm (CR) was identiﬁed by RNA sequencing as
the most dysregulated pathway in human osteoarthritis (OA) knee
articular cartilage. This study examined circadian rhythmicity in cul-
tured chondrocytes and the role of the CR genes NR1D1 and BMAL1 in
regulating chondrocyte functions. NR1D1 is a negative regulator of
BMAL1, a core clock gene that regulates circadian rhythmicity.
Methods: RNA was extracted from human cartilage tissues harvested
from normal and OA knees (n¼14 each), and expression levels of NR1D1
and BMAL1 mRNA were assessed by quantitative PCR. NR1D1 protein
expressionwas conﬁrmed by immunohistochemistry in normal and OA
human cartilage, as well as in normal knees and knees with surgically
induced OA of mice. To examine the circadian rhythmicity of gene
expression in cultured chondrocytes isolated from normal human car-
tilage, chondrocytes were synchronized by dexamethasone and har-
vested at 4-hour intervals up to 48 hours for RNA and protein
extraction. Chondrocytes were then treated with small interfering RNA
(siRNA) for NR1D1 or BMAL1, followed by IL-1b or TGFb stimulation to
test the effect of knock down on response to IL-1b and TGFb.
Results: Both NR1D1 and BMAL1 mRNA levels were signiﬁcantly
reduced in OA cartilage, compared to normal cartilage. NR1D1 protein
was predominantly expressed in the superﬁcial and upper-mid zone of
normal cartilage, both in human and in mouse knees. The protein
expression was reduced in OA cartilage, although high expression was
observed in cluster cells. In surgically inducedOA inmice,NR1D1protein
expression was signiﬁcantly reduced before cartilage damage occurred.
In cultured human chondrocytes, a clear circadian rhythmicity was
observed for NR1D1 and BMAL1 mRNA levels. NR1D1 expressionwas at
its lowest level at T12 and T36, whereas highest expression was
observed at T24 and T48. The expression pattern of BMAL1 displayed
the reversed pattern. Treatment with siRNA signiﬁcantly suppressed
levels of both genes at all time points, but the rhythmic expression
pattern was preserved for NR1D1. Increased BMAL1 expression was
observed at T24 and T48 after knocking down NR1D1, and decreased
NR1D1 levels were observed at all time points after knocking down
BMAL1. IL-1b treatment signiﬁcantly induced IL6, COX2, iNOS, MMP13
and ADAMTS4. NR1D1 knock down further increased the expression
levels of iNOS, MMP13 and ADAMTS4, while by contrast the IL-1
induction of IL6 and COX2 was blunted. Genome-wide sequencing of
RNA from chondrocytes treated with NR1D1 and BMAL1 siRNA iden-
tiﬁed 330 and 68 genes, respectively, that were signiﬁcantly different.
TGFb signaling pathway was affected by both siRNAs. NR1D1 and
BMAL1 knock down increased the expression of elastin and tenascin C,
following induction by TGFb.
Conclusions: The circadian rhythm pathway is dysregulated in OA
cartilage. Interference with circadian rhythmicity in cultured chon-
drocytes affects IL-1b and TGF-b signaling, which are central pathways
in cartilage homeostasis and OA pathogenesis.
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DIO2-KNOCKOUT MODULATES CIRCADIAN CLOCK GENES IN
ARTICULAR CARTILAGE THROUGH THYROID HORMONE SIGNALING
N. Bomer y,z, F.M. Cornelis x, Y.F. Ramos y, W. den Hollander y,
N. Lakenberg y, R. van der Breggen y, L. Storms x, P.E. Slagboom y,z,
R.J. Lories x,k, I. Meulenbelt y. y LUMC, Leiden, Netherlands; z Integrated
research of Dev.al determinants of Ageing and Longevity (IDEAL), Leiden,
Netherlands; x Lab. of Tissue Homeostasis and Disease, Skeletal Biology
and Engineering Res. Ctr., KU Leuven, Leuven, Belgium; kDiv. of
Rheumatology, Univ. Hosp. Leuven, Leuven, Belgium
Purpose: Previously, the type II deiodinase (D2) gene (DIO2) has been
identiﬁed as relevant OA susceptibility gene. D2 regulates the bio-
availability of intracellular triiodothyronine (T3) and expression of DIO2
mRNA and D2 protein levels in osteoarthritic cartilage are increased as
compared to healthy cartilage. Given the function of T3 signalling this
should be considered detrimetnal to cartilage integrity. In this respect,
we showed that knocking-out Dio2 expression in C57Bl/6 mice, has aprotective effect particularly after administrating a stringent running
regime. Here, we aim to identify intrinsic underlying differences in
articular cartilage tissue homeostasis between wild-type- and Dio2-
knockout-mice.
Methods: Genome wide gene expression data (Illumina MouseWG-6
v2) of knee-cartilage of wild-type and C57Bl/6-Dio2 -/- -mice was used
to detect the involved gene expression pathways. To increase power in
our analysis, probes with a jfold-changej  1.5 between wild-type- and
knockout-mice were analyzed and subsequent multiple test correction
according the “bonferroni-method” was performed. STRING-db and
STITCH analysis was applied to visualize protein-protein (PPI) and
protein-chemical interaction (PCI)-networks.
Results: Comparing the microarray-data of articular cartilage of knock-
out- and wild-type-mice showed 69 probes that were differentially
expressed with a jfold-changej  1.5 whereas 4 probes, representing 4
genes remained signiﬁcant after subsequent multiple testing correction.
Notably, two of these genes are known canonical genes, involved in the
circadian clock rhythm. Except for Calr (FC ¼ -1.73; Padj. ¼ 0.00050),
direct protein interaction (PPI) was found between LOC100047427 (Pre-
dicted: similar to thyroid hormone receptor (Thra); FC ¼ 1.74; Padj. ¼
0.0331) and circadian clock genes, Dbp (FC ¼ 2.61; Padj. ¼ 0.0264) and
Nr1d1 (FC ¼ 1.57; Padj. ¼ 0.0307) (Figure 1A). To visualize the inter-
relationship of this PPIwith respectivelyDio2, T3 and its receptor Thra,we
next added these in a STITCH-db analysis (Figure 1B) and conﬁrmed
interaction of this PPI with thyroid signaling. Furthermore, ChAP-seq
experiments performed by Chatonnet et al; (2013) showed that the
promoters of these genes are under inﬂuence of the thyroid hormone
receptor (THR)-alpha (Dbp) and -beta (Nr1d1) in mice.
Conclusions: We demonstrated that Dio2:-depletion in articular carti-
lage results in signiﬁcanthigherexpressionof circadianclock genesNr1d1
andDbp, likelymediatedvia the thyroidhormone receptors. Furthermore,
our data demonstrates that upregulation of circadian rhythmgenes could,
in part, explain the previously established beneﬁcial effect of articular
cartilage tissue homeostasis of Dio2 knockout mice.
Figure 1. Gene networks in search tool for the retrieval of interacting
genes. (A) Screenshot of the PPI-network for the 4 genes signiﬁcantly
differing >j1.5j-fold between knockout- and wild-type-mice (STRING-db).
(B) Screenshot of the PCI-network for the 4 genes signiﬁcantly differing
>j1.5j-fold between knockout- and wild-type-mice, including Dio2 and
triiodothyronine (T3) (STITCH).
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INCIDENT BISPHOSPHONATE USE AND RISK OF KNEE REPLACEMENT
SURGERY AMONG WOMEN WITH INCIDENT KNEE OSTEOARTHRITIS
T. Neogi, C. Peloquin, Y. Zhang, D. Misra. Boston Univ. Sch. of Med.,
Boston, MA, USA
Purpose: Bone remodeling as a therapeutic target in knee osteoarthritis
(OA) has gainedmuch interest, but the effects of antiresorptive agents on
knee OA have been conﬂicting. Since mechanical factors play a central
role in knee OA and bone adapts readily to mechanical stresses, it is
important to understand the effects of modulating bone remodeling via
antiresorptive agents such as bisphosphonates on the course of knee OA.
We assessed the relation of incident bisphosphonate use to the risk of
knee replacement (KR) surgery among women with incident knee OA.
Methods: We used data from The Health Improvement Network
(THIN), a general practitioner (GP) electronic medical records database
representative of the UK general population. We included women aged
50-89 with incident knee OA between 1/1/2003-12/31/2012 who had
1 GP visit or 1 prescription during the one year prior to the knee OA
diagnosis. We excluded womenwith existing KR (prior to incident knee
OA or bisphosphonate use), those less likely to be KR candidates
(BMI>40, history of joint infection, high risk cancers (pancreatic,
esophageal, gastric or other metastatic), dialysis, supplemental oxygen,
Table
Relation of incident bisphosphonate use to risk of incident KR among older women with incident knee OA
Analytic Approach Incident Bisphosphonate User Non-Bisphosphonate User Crude HR (95% CI) Adjusted HR* (95% CI)
PS*-matched
N 1964 1964
Mean OA duration 4.4 ± 3.5years 4,5 ± 3,5 years
Crude incidence rate per 1000 person-years 21.45 28.94 0.75 (0.59-0.94) 0.76 (0.61-0.96)
BMI-and age-matched
N 1869 5017
Mean OA duration 4.6 ± 3.5 years 3.1 ± 2,9 years
Crude incidence rate per 1000 person-years 24.37 60.62 0.40 (0.33-0,49) 0.40 (0.30-0.53)
*Variables included in PS model and included in the “Adjusted HR” model: 1) OA severity and duration 2) General (age, gender, BMI, socioeconomic status); 3) Comorbidities
(osteoporosis-related (osteoporosis, hip fracture, vertebral fracture, number of bone mineral density measurements), hypertension, diabetes (including severity), hyper-
lipemia, ischemic heart disease (including severity), heart failure, atrial ﬁbrillation, stroke, dementia/cognitive impairment, depression, seizure disorder, venous throm-
boembolism, chronic obstructive lung disease, pneumonia, renal disease, liver disease, cancers except skin cancer, cellulitis, falls, inﬂammatory arthritis, arid peptic ulcer
disease); 4) Habits (smoking status and alcohol use); 51 Health status (number of GP visits and hospitalization, albumin level); and 6) Medication use (Non-steroidal anti-
inﬂammatory medications, opioid or non-opioid analgesics, anti-hypertensive, cholesterol lowering, insulin/oral hypoglycemic, glucocorticoids (systemic and inhaled),
estrogens, and anti-epileptics)
Table 1
Differences between atrophic OA knees vs. non-atrophic OA knees regarding pro-
gression of JSN and progression of cartilage loss, using both (radiographic and MRI)
deﬁnitions of atrophic vs. non-atrophic knee OA.
Progression of JSN
(Radiographic deﬁnition)
Atrophic OA
knees
Non-atrophic
OA knees
p-vaiues
No progression 54/77 (70%) 224/373 (60%)
Slow progression 22/77 (29%) 143/373 (38%) 0.25
Fast progression 1/77 (1%) 6/373 (2%)
Progression of
Cartilage Loss
(Radiographic
deﬁnition)
Atrophic OA
knees
Non-atrophic
OA knees
No progression 45/77 (58%) 171/373 (46%) 0.12
Slow progression 13/77 (17%) 91/373 (24%)
Fast progression 19/77 (25%) 111/373 (30%)
Progression of
JSN (MRI
deﬁnition)
Atrophic OA
knees
Non-atrophic
OA knees
No progression 30/50 (60%) 248/400 (62%)
Slow progression 19/50 (38%) 146/400 (36%) 0.94
Fast progression 2/50 (1%) 6/400 (2%)
Progression of
cartilage loss
(MRI deﬁnition)
Atrophic OA
knees
Non-atrophic
OA knees
No Progression 29/50 (58%) 187/400 (47%)
Slow Progression 12/50 (24%) 92/400 (23%) 0.17
Fast Progression 9/50 (18%) 121/400 (30%)
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nate or bone-modulating therapy. We identiﬁed women who had
incident (ﬁrst) prescription of a bisphosphonate (i.e., alendronate,
etidronate-calcitonin, ibandronate, pamidronate, risedronate, zolendr-
onate) after their incident (new onset) knee OA diagnosis. We com-
puted propensity scores (PS) using logistic regression, with incident
bisphosphonate use as the dependent variable and potential con-
founders that reﬂect indication for bisphosphonate use and for KR
(Table) as the independent variables. Each incident bisphosphonate
user wasmatched 1:1 with an unexposed subject with greedymatching
using the PS within 1-year cohort accrual blocks. Follow-up started
from the index date (date of 1st bisphosphonate prescription for the
exposed, and randomly assigned to the unexposed within the one-year
accrual block), and continued until KR, death, censoring, or end of study.
The relation of incident bisphosphonate use to KR among women with
incident knee OA was assessed using Cox proportional hazard models.
Because body mass index (BMI) is an important confounder, we con-
ducted separate analyses in which incident bisphosphonate users were
matched by BMI (±0.5kg/m2) and age (same birth year) to up to 4
unexposed subjects, and variables used in the PS model were addi-
tionally adjusted for in this model.
Results: In the PS-matched approach, we identiﬁed 1964 incident
bisphosphonate users who were matched to 1964 non-users (mean age
76, mean BMI 27.4), withmean follow-up time of 3 years. Themean (SD)
age at incident knee OAdiagnosis was 72 (8), at incident bisphosphonate
prescription was 76 (8), and at KR was 75 (7). Overall, covariates were
well-balanced in the two groups. The crude incidence rate of KR among
incident bisphosphonate users was 21.45 per 1000 person-years, and
28.94 per 1000 person-years among the non-users. The PS-matched
model hazards ratio (HR)was 0.75 (95% CI 0.59-0.94).When additionally
adjusted for the potential confounders included in the original PSmodel,
the effect estimate remained unchanged (Table). In the BMI- and age-
matched cohort approach (N¼1869 incident users; 5017 matched non-
users), the effect estimates remained protective (Table).
Conclusions: In this large cohort of older women with incident knee
OA, those with incident bisphosphonate use had a lower risk of KR than
non-users. While we cannot rule-out potential for residual confounding
(e.g., confounding by indication) or possible depletion of susceptibles
(i.e., women who had a KR prior to incident bisphosphonate use were
excluded), these results suggest that bisphosphonates may have bene-
ﬁcial effects on knee OA.
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THE ATROPHIC PHENOTYPE OF KNEE OSTEOARTHRITIS (OA) IS NOT
ASSOCIATED WITH MORE RAPID PROGRESSION OF DISEASE WHEN
COMPARED WITH THE NON-ATROPHIC PHENOTYPE: THE MOST
STUDY
M.D. Crema y, D.T. Felson y, A. Guermazi y, M.C. Nevitt z, E.K. Quinn y,
J. Niu y, J.A. Lynch z, M.D. Marra y, J. Torner x, C.E. Lewis k, F.W. Roemer y.
yBoston Univ., Boston, MA, USA; zUniv. of California at San Francisco, San
Francisco, CA, USA; xUniv. of Iowa, Iowa City, IA, USA; kUniv. of Alabama,
Birmingham, AL, USA
Purpose: In knees exhibiting fast progression of cartilage loss over time,
osteophyte formation may lag behind cartilage loss, which might thenmanifest as an atrophic phenotype of knee osteoarthritis (OA). Cases of
rapidly progressive OA were observed as a potential adverse event in
studies evaluating efﬁcacy of nerve growth factor inhibitors (aNGF). The
atrophic phenotype of OA is believed to be a predisposing entity tomore
rapid progression of OA. To support the hypothesis that atrophic OA is
associated with faster progression of disease, we assessed the associa-
tions of the presence of the atrophic phenotype of tibiofemoral OA at
baseline with progression of radiographic JSN and MRI progression of
cartilage loss over 30 months.
Methods:MOSTstudy participants with available OARSI grading system
scores of tibiofemoral JSN and osteophytes on radiographs (from 0 to 3),
tibiofemoralWORMS grades onMRI for cartilagemorphology (from 0 to
6) and osteophytes (from 0 to 7) for all ten subregions, as well as
WORMS grades on MRI for meniscal morphology (from 0 to 4) and
meniscal extrusion (from 0 to 3) bilaterally, performed at baseline and
30 months follow-up (FU), were included. Based on baseline radio-
graphs, the atrophic phenotype of tibiofemoral OAwas deﬁned as OARSI
grades 1 or 2 for JSN and grade 0 (absence) for osteophytes. Non-atro-
phic knee OA was deﬁned as OARSI grades 1 or 2 with osteophytes
grades 2 or 3. Based on baseline MRI, atrophic knee OA was deﬁned as
tibiofemoral severe cartilage damage (grades 5 or 6) in at least 1 of 10
subregions with absent or tiny osteophytes (grades 0 to 2) in all tibio-
femoral subregions. Regarding progression of JSN on radiographs from
baseline to FU, three groups were deﬁned: no progression (no increase
in OARSI grade in both tibiofemoral compartments), slow (an increase
